Thrombin decreases the platelet surface expression of the glycoprotein (GP) Ib-IX complex. To determine whether this effect is reversible, flow cytometric studies were performed with GPlb-IX-specific monoclonal antibodies. In both whole blood and washed platelet systems, incubation of platelets with thrombin or a combination of adenosine diphosphate and epinephrine resulted in a maximal decrease of the platelet surface expression of GPlb-IX within 5 minutes, after which there was a time-dependent return of the platelet surface GPlb-IX complex, which was maximal by 60 minutes.
were preincubated with a biotinylated GPlb-specific MoAb showed that the GPlb molecules that returned to the platelet surface were the same molecules that had been transiocated to the intraplatelet pool. The GPlb molecules that returned to the platelet surface were functionally competent t o bind von Willebrand factor, as determined by ristocetin-induced platelet agglutination and ristocetin-induced binding of exogenous von Willebrand factor. Inhibitors of protein kinase C and myosin light-chain kinase enhanced the reexpression of platelet surface GPIb. In summary, the activation-induced decrease in the platelet surface expression of the GPb-IX complex is reversible. Inactivation of protein kinase C and myosin light-chain kinase are important mechanisms in the reexpression of the platelet surface GPb-IX complex. release from the platelets of glycocalicin (a proteolytic fragment of GPIb),9 and (4) a parallel decrease in the platelet surface binding of a panel of monoclonal antibodies (MoAbs) directed against GPIb, GPIX, and the GPIb-IX cornplex,'j,'' whereas proteolysis of GPIb only results in a decrease in the binding of GPIb-specific MoAbs." The thrombin-induced decrease in the platelet surface expression of the GPIb-IX complex appears to be the result of a translocation of GPIb-IX to the membranes of the open-surface canalicular system." Adenosine diphosphate (ADP) and the stable thromboxane A2 analogue, U46619, also decrease the platelet surface expression of the GPIb-IX complex, whereas epinephrine has little effect.'*" ' In the present study, we examined the hypothesis that the activation-induced decrease in the platelet surface expression of the GPIb-IX complex is reversible.
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There are no centrifugation, gel filtration, vortexing, or stimng steps that could artefactually activate platelets. Peripheral blood was drawn from healthy adult volunteers who had not ingested aspirin or other antiplatelet drugs during the previous 10 days, except as indicated in experiments in which the volunteer ingested 700 mg of aspirin 2 hours before phlebotomy. The first 2 mL of blood drawn were discarded and then blood was drawn into a sodium citrate Vacutainer (Becton Dickinson, Rutherford, NJ), which does not result in platelet a~tivation.~' Within 15 minutes, the anticoagulated blood was diluted 1:2 by volume in modified Tyrode's buffer (137 mmol/L NaCI, 2.8 mmol/L KCl, 1 mmovL MgClz, 12 mmol/L NaHC03, 0.4 mmol/L Na2HF'04, 0.35% bovine serum albumin [BSA] , IO mmol/L HEPES, 5.5 mmol/L glucose, pH 7.4) with 2.5 mmoliL (final concentration) of glycyl-L-prolyl-L-arginyl-L-proline (GPRP) (Calbiochem, San Diego, CA) (an inhibitor of fibrin polymerization and platelet aggregation"), and incubated at 37°C with an equal volume of platelet agonist or control buffer. The following agonists were studied: purified human a-thrombin (provided by Dr John Fenton II, New York Department of Health, Albany); phorbol myristate acetate (PMA) (Sigma Chemical CO, St Louis, MO); the stable thromboxane Az analogue, U46619 (Cayman Chemical, Ann Arbor, MI); ADP (BioData, Horsham, PA); epinephrine (BioData); platelet activating factor ( P m ) (Sigma); and vasopressin (Sigma).
Inhibitors were included in some experiments as follows: (1) Hirudin IO U/mL (Calbiochem) (a specific thrombin inhibitor) was coincubated with ADP and epinephrine; (2) an inhibitor of protein kinase C, either staurosporine 10 pmoVL (Sigma) or l-0-alkyl-2-O-methylglycerol (AMG)" 125 pmol/L (Cayman Chemical), was added 15 minutes after either PMA or U46619; (3) either wortmannin 5 pmoV L (Sigma) (an inhibitor of myosin light-chain kinase") or cytochalasin B 6 pmol/L (Sigma) (an inhibitor of actin p~lymerization'~) was added 15 minutes after thrombin; (4) 5-(N-ethyl-N-isopropy-1)amiloride (EIA) 20 pmoVL (a specific inhibitor of Na'/H' ex~h a n g e~~. '~) (obtained from Merck, Sharp, and Dohme, West Point, PA) was incubated with the sample at 37°C for 15 minutes before the addition of thrombin.
All samples were fixed with 1% formaldehyde at various time points after the addition of the agonist. Samples were then diluted and incubated at 22°C for 15 minutes with a saturating concentration of a biotinylated MoAb (directed against either the GPIb-M complex or P-selectin) and a subsaturating concentration of the FITC-conjugated GPIIIa-specific MoAb, Y2/51. The samples were then incubated at 22°C for 15 minutes with phycoerythrin-streptavidin (Jackson Immunoresearch Laboratories, West Grove, PA). Within 24 hours of antibody tagging, the samples were analyzed in an EPICS Profile flow cytometer (Coulter Cytometry, Hialeah, E). After identification of platelets by gating on both FITC positivity and their characteristic light scatter, binding of the biotinylated MoAb was determined by analyzing 5,000 individual platelets for phycoerythrin mean fluorescence. To compare results in linear form, data obtained from fluorescence channels in a logarithmic mode were converted to their linear equivalents. As indicated in the figure legends, the binding of the GPIb-specific MoAb before the addition of thrombin was assigned 100 linear U fluorescence. The binding of the P-selectin-specific MoAb 5 minutes after the addition of thrombin 1 U/ mL was assigned 100 linear U fluorescence. We" and others36 have shown that this method results in no significant differences in fluorescence intensity between samples analyzed immediately and samples analyzed within 24 hours of antibody tagging.
In experiments to determine whether there was proteolytic loss of GPIb from platelets, a saturating concentration of FITC-conjugated MoAb 6D1 was added 15 minutes before the addition of thrombin 0.5 U/mL and GPRP 2.5 mmoliL. The samples were then fixed at various time points, diluted, incubated (22"C, 15 minutes) with a saturating concentration of a biotinylated MoAb WM23, incubated (22"C, 15 minutes) with phycoerythrin-streptavidin, and analyzed for FITC and phycoerythrin fluorescence by flow cytometry.
Flow Cytometric Analysis of the Platelet Sugace GPIb-IX

Complex in a Washed Platelet System
The method has been described previo~sly.~~.~' The first 2 mL of blood drawn were discarded and then blood was drawn into a sodium citrate Vacutainer. The anticoagulated blood was centrifuged (150g, 15 minutes, 22°C) and the platelet-rich plasma removed and diluted with 3 volumes of citrate-albumin buffer (1 1 mmom glucose, 128 mmol/L sodium chloride, 4.3 mmoVL monobasic sodium phosphate, 7.5 mmoVL dibasic sodium phosphate, 4.8 mmoVL sodium citrate, 2.4 mmol/L citric acid, 0.35% BSA), pH 6.5 with prostaglandin El (PGE,) 50 ngimL. Platelets were separated from plasma by centrifugation (1,2OOg, 10 minutes, 22°C) and gentle resuspension in citratealbumin buffer, pH 6.5 with PGE, 50 ng/mL. After an additional centrifugation (1,20Og, IO minutes, 22"C), the platelets were resuspended in modified Tyrode's buffer, pH 7.4. The washed platelets (75,OOO/pL) were incubated at 37°C with various concentration of human a-thrombin (or control buffer). At various time points up to 2 hours, aliquots were fixed for 30 minutes at 22°C and diluted 10-fold in modified Tyrode's buffer, pH 7.4. Samples were then incubated with a saturating concentration of an FITC-conjugated GPIb-IX complex-specific MoAb, and analyzed by flow cytometry. In some experiments, 50 pg/mL of cycloheximide (Sigma) (an inhibitor of protein synthesis) was added together with the thrombin. In other experiments, hirudin 10 U/mL was added 5 minutes after the addition of thrombin.
In experiments to determine whether the GPIb molecules that returned to the platelet surface were the same molecules that had been translocated to the intraplatelet pool, washed platelets were prelabeled with a saturating concentration of biotinylated WM23, washed free of excess antibody, and incubated with thrombin 0.1 U/mL, thrombin 0.2 UlmL, or control buffer. The samples were fixed at various time points, incubated with phycoerythrin-streptavidin and a saturating concentration of FITC-conjugated 6D1, and the binding of WM23 and 6D1 assessed by flow cytometry.
Ristocetin-Induced Binding of vWf to Platelets
The ristocetin-induced binding of vWf to platelets was determined by a previously described method." Washed platelets were incubated with various concentrations of human a-thrombin (or control buffer). At various time points up to 2 hours, aliquots were fixed with 1% formaldehyde for 30 minutes at 22T, diluted 40-fold with modified Tyrode's buffer, pH 7.4, and incubated (22"C, 15 minutes) with pooled platelet-poor plasma from normal donors (as a source of vWf) and ristocetin (BioData) (final concentration 1.4 mg/mL). The mixture was then incubated (22"C, 15 minutes) with 28 p g / d of either polyclonal FITC-conjugated anti-vWf goat IgG antibody (Atlantic Antibodies, Stillwater, MN) or FITC-conjugated nonspecific goat IgG (Atlantic Antibodies). The sample was then diluted 16-fold in modified Tyrode's buffer, pH 7.4 and analyzed by flow cytometry. The fluorescence of the sample incubated with the nonspecific goat IgG was subtracted from the fluorescence of the sample incubated with the anti-vWf antibody.
Plasma Glycocalicin Assay
Plasma glycocalicin was determined by a competitive inhibition assay, as previously de~cribed.~' Under the conditions described below, saturation of the platelet binding of MoAb 6D1 occurred at 1.7 pg/mL. A subsaturating concentration (1.2 pg/mL) of FITCconjugated MoAb 6D1 was incubated at 22°C for 20 minutes with either test plasma that had been filtered through a 0.22-pm Acrodisc (Gelman, Ann Arbor, MI) and had the pH buffered to 7.4, or various 3564 concentrations of purified glycocalicin. Samples were then incubated at 22°C for 20 minutes with fixed, washed platelets (final concentration 100,00O/pL) and diluted 20-fold in modified Tyrode's buffer, pH 7.4 before the platelet binding of 6D1 was analyzed by flow cytometry. Linear regression analysis was used to generate a standard curve from the purified glycocalicin samples. This standard curve, which was repeated with every experiment, always showed linearity between 0 and 70 nmol/L of glycocalicin. The correlation coefficient ( r ) was always greater than 0.96. The plasma glycocalicin concentration of unknown plasma samples was derived from the standard curve. All assayed samples were within the linear range of 0 to 70 nmol/L.
Ristocetin-Induced Platelet Agglutination
Platelets (250,00O/pL) suspended in autologous plasma were stirred with 1.2 mg/mL ristocetin in a Lumi-Aggregation Module Series 10008 (Payton, Buffalo, NY). Platelet agglutination was detected by change in light transmission, as previously described.'R
RESULTS
Reversibility of the Thrombin-Induced Decrease in the Platelet Sudace Expression of the GPlb-IX Complex
Thrombin has previously been shown to rapidly decrease the platelet surface expression of the GPIb-IX c~mplex."'~ To determine whether this effect was reversible, diluted whole blood was incubated with thrombin and aliquots were fixed at various time points for up to 2 hours (Fig 1) . The platelet surface expression of the GPIb-IX complex was analyzed by a whole blood flow cytometric assay using MoAb 120 40 MICHELSON ET AL 6D1 (directed against the vWf binding site on GPIba). Inclusion of the peptide GPRP (an inhibitor of fibrin polymerization and platelet aggregation) allowed us to study the effect of purified human a-thrombin on individual platelets in whole blood." As expected, there was a rapid, concentrationdependent decrease in the platelet surface expression of the GPIb-IX complex, with a maximal decrease at 5 minutes (Fig 1) . However, further incubation resulted in a gradual return of the platelet surface expression of the GPIb-IX complex (Fig 1) . The return of the platelet surface expression of the GPIb-IX complex was maximal at approximately 60 minutes. Stimulation with lower concentrations of thrombin (0.05 to 0.3 U/mL) resulted in complete reversibility of the platelet surface expression of GPIb within 60 minutes, whereas stimulation with a high concentration of thrombin (2 UlmL) resulted in incomplete reversibility with 20% of the GPIb not returned to the platelet surface (Fig l ) . This 20% apparently remained within the platelet because there was no proteolysis of GPIb (see below).
Reversibility of the thrombin-induced decrease in the platelet surface expression of the GPIb-IX complex was also shown in a washed platelet system (Fig 2) . Because each platelet is analyzed individually, the flow cytometric method of analyzing platelet surface GPIb is able to detect distinct subpopulations of platelets. Log Fluorescence surface expression of the GPIb-IX complex was not confined to a distinct subpopulation of platelets.
In both whole blood and the washed platelet system, a parallel and quantitatively similar reversibility of the thrombin-induced decrease in the platelet surface expression of the GPIb-DC complex was also shown with three other MoAbs that are directed against different epitopes than 6D1: (1) TM60 (directed against the thrombin and vWf binding sites on GPIba), (2) W 2 3 (directed against the macroglycopeptide portion of GPIbcu), and (3) AKI (directed against the GPIb-IX complex) (n = 3, data not shown). The fact that AKl only binds to the intact GPIb-DC complex, not to uncomplexed GPIb or GPIX," shows that the GPIb and GPIX molecules reexpressed on the platelet surface are fully complexed.
Reversibility of the Thrombin-Induced Decrease in the Binding of vWf to the Platelet Surface GPIb-IX Complex
Thrombin has previously been shown to decrease the binding of vWf to the platelet GPIb-IX complex." To determine whether this effect was reversible, washed platelets were incubated with thrombin, aliquots were fixed at various time points up to 2 hours, and the ristocetin-induced binding of vWf to platelets determined by flow cytometry (Fig 3) . As expected, there was a rapid decrease in the ristocetin-induced binding of vWf to platelets, with a maximal decrease at 5 minutes. Further incubation resulted in a gradual return in the ability of platelets to bind vWf in response to ristocetin (Fig 3) .
The effects of thrombin on vWf binding and on the binding of a GPIb-specific MoAbs (6D1) were directly compared by analyzing aliquots of the same washed platelets (compare the closed circles in Fig 3 to the closed circles in Fig 4B) . The data show that almost all the GPIb molecules that returned to the platelet surface were competent to bind vWf. Reversibility of the thrombin-induced decrease in the binding of vWf to the platelet surface GPIb-D( complex was also shown by ristocetin-induced platelet agglutination (data not shown).
It should be noted that apparent differences in the degree of effect of thrombin between different figures in this study are accounted for by the fact that some of the experiments were performed in whole blood (eg , Fig l) , whereas others were performed in a washed platelet system (eg, Fig 3) . The presence of antithrombin I11 in the plasma portion of whole blood resulted in a more modest effect for a given dose of thrombin, as compared with the washed platelet system in which no antithrombin 111 was present. In the whole blood system of Fig 1, thrombin 0 .2 U/mL resulted in a modest return in the platelet surface expression of GPIb that was equivalent to complete reversibility because the initial decrease in the platelet surface expression of GPIb was also only modest. In contrast, in the washed platelet system of Fig 3, thrombin 0 .2 U/mL resulted in a more substantial percent return of the platelet surface expression of GPIb, but this was equivalent to only partial reversibility because the initial decrease in the platelet surface expression of GPIb was much more substantial.
The GPIb Molecules That Returned to the Platelet Surface Were the Same Molecules That Had Been Translocated to the Intraplatelet Pool
The thrombin-induced decrease in the platelet surface expression of the GPIb-IX complex has previously been shown to be on the basis of a redistribution of GPIb-IX complexes to the membranes of the open surface canalicular system." To determine whether the GPIb molecules that returned to the platelet surface were the same molecules that had been translocated to the intraplatelet pool, the following experiment was performed. Washed platelets prelabeled with biotinylated W 2 3 (a GPIb-specific MoAb) were activated with thrombin, fixed at various time points, diluted IO-fold, incubated with phycoerythrin-streptavidin and FITC-conjugated 6D1 (a GPIb-specific MoAb directed against an epitope distinct from WM23), and the binding of phycoerythrinstreptavidin and 6Dl assessed by flow cytometry (Fig 4) .
Before the addition of thrombin, the biotinylated WM23 was accessible to the phycoerythrin-streptavidin (Fig 4A, 0 After the thrombin-induced redistribution of the GPIb-IX complexes, the biotinylated W 2 3 was inaccessible to the phycoerythrin-streptidin (Fig 4A, S-minute, 10 minute, and 15-minute time points). (The residual approximately 25% phycoerythrin fluorescence was the result of the minority of GPIb molecules that were not translocated to the intraplatelet po01.~~,~* After further incubation, the biotinylated WM23 was again accessible to phycoerythrin-streptavidin (Fig 4A, 60 minute and 120 minute time points) .
FITCdDl binding to the same platelets showed the expected reversible thrombin-induced decrease in the platelet surface expression of the GPIb-IX complex (Fig 4B) . Similar results were obtained with thrombin 0.1 U/mL (n = 3, data not shown) and 0.2 U/mL (n = 3 , Fig 4) .
Exposure of Platelets to Additional Exogenous Thrombin Results in a Repetition of the Reversible Decrease in the Platelet Suflace GPlb-IX Complex
We next addressed the question as to whether the same platelets could reversibly decrease their surface expression of the GPIb-IX complex more than once. Figure 5 shows that when platelets were exposed to additional exogenous thrombin 90 minutes after their first exposure to exogenous thrombin, there was a second decrease in platelet surface GPIb-IX, followed by a second reconstitution of the platelet 
Reversibility of the Thrombin-Induced Decrease in the Platelet Sugace Expression of the GPIb-IX Complex Is Not Associated With GPIb Proteolysis
In whole blood experiments in which FITC-conjugated 6D 1 was added before the addition of thrombin, the expected initial decrease and subsequent return in phycoerythrin fluorescence (reflecting accessibility of biotinylated Wh423) was observed. In contrast, FITC fluorescence remained constant, showing that there was no proteolytic loss of GPIb from the platelets during the loss and restoration of the platelet surface expression of GPIb (n = 2, data not shown). This conclusion was supported by the fact that the reversible thrombin-induced 
Restoration of the Platelet Surface Expression of the GPlb-IX Complex Can Occur in a Fully Degranulated Platelet
As expected, the decrease in the platelet surface expression of the GPIb-IX complex induced by thrombin 1 U/mL was associated with translocation of P-selectin to the platelet surface (Fig 6, A and B , 5-minute time point, solid circles). However, the return of the platelet surface expression of the GPIb-IX complex was not associated with any change in the platelet surface expression of P-selectin (Fig 6, A and B , 60-minute time point, solid circles).
Thrombin I s Not Required for the Reexpression of the GPlb-IX Complex on the Platelet Sulface
Hirudin inhibits the action of thrombin on platelets and rapidly removes thrombin from its platelet recept0rs.4~ The addition of 10 U/mL hirudin 5 minutes after the addition of thrombin 0.1 U/mL to washed platelets had no significant effect on the reexpression of the GPIb-IX complex on the platelet surface (data not shown). Thus, the presence of thrombin is not required for the reexpression.
Reversibility of the ADP and Epinephrine-Induced Decrease in the Platelet Surface Expression of the GPlb-IX Complex
ADP and epinephrine synergistically decrease the platelet surface expression of the GPIb-IX complex (Fig 7) . Prolonged incubation with ADP or the combination of ADP and epinephrine resulted in a gradual return of the platelet surface expression of the GPIb-IX complex. This reversible decrease in the platelet surface GPIb-IX complex was not the result of trace amounts of thrombin because the results were unchanged by inclusion in the assay of hirudin, a potent inhibitor of thrombin (data not shown).
Augmentation of the ADP-induced decrease in the platelet surface expression of the GPIb-DC complex was also obtained with the combination of ADP 10 p m o K and PAF 100 n m o K and the combination of ADP 10 pmol/L and vasopressin 5 IU/mL (data not shown). As observed for the ADP/epinephrine combination, the decreases in the platelet surface GPIb-IX complex induced by ADPPAF and ADP/ vasopressin were reversible.
Biochemical Mechanism of the Reexpression of the GPlb-IX Complex on the Platelet Surface
To determine the mechanism by which the thrombin-induced redistribution of the GPIb-IX complex occurs, intraplatelet signaling pathways were perturbed by various pharmacologic manipulations. Platelets were pretreated in vitro with EIA, a specific inhibitor of Na+/H+ e~c h a n g e ,~~.~' or in vivo with oral aspirin 700 mg 2 hours before phlebotomy. Neither EL4 nor aspirin had any effect on the thrombininduced decrease in the platelet surface expression of GPIb or on the subsequent reexpression of GPIb on the platelet surface (n = 3, data not shown). Experiments with the direct protein kinase C activator PMAM and the protein kinase C inhibitor staurosporine suggested that protein kinase C may be involved in effecting the decrease in the platelet surface expression of GPIb, and that inhibition of protein kinase C may reverse this process (Fig 8A) . To determine if protein kinase C activity generated by a receptor-induced activation of phospholipase C inhibits the redistribution of GPIb, platelets were stimulated with the synthetic endoperoxide U46619. U46619 resulted in an irreversible decrease in the platelet surface expression of GPIb (Fig 8B) . However, addition of a protein kinase C inhibitor (either staurosporine or Ah4G) 15 minutes after U46619 resulted in reexpression of platelet surface GPIb (Fig 8B) . The fact that the time course of the PMA-induced decrease in the platelet surface expression of GPIb was slower than that of thrombin suggested that additional second messengers are involved when thrombin is the agonist. Addition of the myosin light-chain kinase inhibitor wortmannin 15 minutes after thrombin enhanced the reexpression of platelet surface GPIb (Fig 9) . However, cytochalasin B, an inhibitor of actin polymerization, had no effect on the reexpression of platelet surface GPIb (Fig 9) .
DISCUSSION
It has previously been shown that thrombin decreases the platelet surface expression of the GPIb-IX complex (a receptor for V W~) .~"~ The following novel conclusions can be drawn from this study: (1) The thrombin-induced decrease in the platelet surface expression of the GPIb-IX complex is reversible, both in a washed platelet system and in whole blood. (2) The loss and restoration of the platelet surface expression of the GPIb-IX complex is not confined to a distinct subpopulation of platelets. In addition, to determine the biochemical mechanism by which the thrombin-induced redistribution of the GPIb-IX complex occurs, intraplatelet signaling pathways were selectively inhibited. In platelets, arachidonic acid is released when phospholipase Az cleaves the C-2 acyl group from membrane phospholipids, particularly phosphatidylchol i ne!5 This step may be regulated by the platelet Na+/H+ exchanger.& Released arachidonic acid is then converted to the metabolically active prostaglandin endoperoxides and thromboxane A2 by the activity of cyclooxygenase (PGG21 PGHz synthase complex). Pretreatment of platelets in vitro with EIA (a specific inhibitor of Na+/H+ e x~h a n g e~~.~~) or in vivo with aspirin had no effect on the thrombin-induced decrease in the platelet surface expression of GPIb or on the subsequent reexpression of GPIb on the platelet surface. These data show that neither the release and metabolism of arachidonic acid nor signal pathways mediated by phospholipase A2 and cyclooxygenase are required for the thrombininduced redistribution of GPIb.
The major signaling pathway involved in platelet activation in response to thrombin is mediated by phospholipase Thrombin binding to and cleavage of its receptor causes the dissociation of a heterotrimeric GTP-binding protein. This dissociation is, through unknown mechanisms, coupled to phospholipase C activation, resulting in the generation of the second messengers diacylglycerol and inositol 1,4,5-triphosphate. Diacylglycerol causes the activation of protein kinase C, which promotes platelet secretion and regulates various metabolic pr0cesses.4~ Inositol 1,4,5-triphosphate causes the release of stored calcium and the activation of calciudcalmodulin-dependent protein kinases, the best characterized of which is myosin light-chain kina~e.4~ Myosin light-chain kinase phosphorylates myosin, which leads to the cytoskeletal assembly required for shape change and secretion?' Experiments with the direct protein kinase C activator PMA and the protein kinase C inhibitor staurosporine suggested that protein kinase C may be involved in effecting the decrease in the platelet surface expression of 0 U46619 V U46619 with atauroaporine v U46619 with AMG added added after 15 rnin GPIb, and that inhibition of protein kinase C may reverse this process. To corroborate this, the synthetic endoperoxide U46619, together with a protein kinase C inhibitor (staurosporine or AMG), was used. These experiments showed that protein kinase C activity, generated by receptor-induced activation of phospholipase C, inhibits the reexpression of platelet surface GPIb. It was also observed that wortmannin, a myosin light-chain kinase enhanced the reexpression of platelet surface GPIb. However, cytochalasin B, an inhibitor of actin polymerization that blocks the thrombininduced decrease in the platelet surface expression of GPIb,'os'2 had no effect on the reexpression of platelet surface GPIb. Thus, our data show that both protein kinase C and myosin light-chain kinase, second messengers formed by thrombin-induced platelet phospholipase C activation, inhibit the reexpression of platelet surface GPIb. Inactivation of protein kinase C and myosin light-chain kinase appear to be important mechanisms in the reexpression of platelet surface GPIb. The time frame of the start of the reexpression of platelet surface GPIb (approximately 10 sulted in a reversible decrease in the platelet surface expression of the GPIb-IX complex. The use of nonphysiologic agonists (PMA or U46619) resulted in an irreversible decrease in the platelet surface expression of the GPIb-IX complex. Because PMA causes a direct and prolonged stimulation of protein kinase the reexpression of platelet surface GPIb is suppressed. In contrast, the activation of protein kinase C in response to thrombin or ADP is of shorter duration and less magnitude than PMA. We speculate that the duration of protein kinase C activation in response to U46619 is longer than thrombin, perhaps because of the stability of U46619 (as distinct from the instability of native thromboxane A*).
There are precedents for redistributions of glycoprotein receptor molecules between intraplatelet and platelet surface membrane pools. For example, we have previously reported that after plasmin-mediated proteolysis of platelet surface GPIb, platelets can replenish their surface GPIb pool (within a similar time frame to that reported in this study for thrombin) by recruitment of GPIb molecules from the intraplatelet pool (or from a sequestered surface ~ite)..'~ An immunoelectron microscopic study, published after submission of this 3571 manuscript for review, reported that the thrombin-induced translocation of platelet surface GPIb to the surface-connected canalicular system is rever~ible.4~ Furthermore, the GPIIb-IIIa complex is able to actively cycle between intraplatelet and platelet surface pools.so Finally, in human cells lines, the tethered ligand thrombin receptor is rapidly internalized after the addition of thrombin.s' Resensitization of the cells to activation by tethered ligand peptides is associated with the return of receptors to the cell surface."
The pathophysiologic significance of the reversibility of the activation-induced decrease in the platelet surface expression of the GPIb-IX complex remains to be determined. However, previous studies have shown that platelets fully degranulated by thrombin, though they have no granule contents to release, can function normally, including aggregate in response to additional thrombin and circulate in V~V O . '~-~~ The present study shows that fully degranulated platelets can reexpress the GPIb-IX complex on their surface. Given that the GPIb molecules that return to the platelet surface are functionally competent to bind vWf, they may be able to participate in platelet adhesion. Furthermore, these platelets can be activated again, and reexpress their platelet surface GPIb-IX complex a second time. Thus, consistent with previous st~dies;~-'~ the present experiments show that a fully degranulated platelet can still be activated, as defined by thrombin-induced modulation of the platelet surface GPIb-IX complex. Taken together, this and previous ~tudie?~"' suggest that after platelets are activated and degranulated, they may still be able to function. Indeed, it has been proposed that platelets that have been degranulated by thrombin and have taken part in thrombus formation can return to the circulation, where they may contribute to the promotion of hemostasis andor thrombosis." We are currently examining this hypothesis in vivo in a nonhuman primate model.
Because of its central role in platelet adhesion and its binding sites for vWf and thrombin," the GPIb-IX complex is frequently measured in both in vitro and in vivo studies of platelets. A practical implication of the present data is that in a given in vitro or in vivo experiment, the results of measurements of the platelet surface GPIb-IX complex may vary according to the time point at which samples are analyzed or fixed.
